Femasys Stock Forum

$Femasys (FEMY.US)$ Reuters· 4 mins ago
Femasys Announces Partnership With Hrc Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer Femaseed

$Femasys (FEMY.US)$
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed

$Femasys (FEMY.US)$ Femasys Announces Peer-Reviewed Publication Of FemaSeed Data In The Journal of Gynecology & Reproductive Medicine

$Femasys (FEMY.US)$ Femasys Gets FDA 510(k) Substantially Equivalent Decision Of Its FemVue MINI Saline-Air Device On November 22, 2024

$Femasys (FEMY.US)$
Femasys Inc., a leading biomedical company, has filed an amended Form 8-K/A with the SEC to correct previously reported dates. The amendment, dated November 12, 2024, rectifies the 'Date of Report' and related references from August 12, 2024, to the correct date of November 12, 2024. Alongside this administrative correction, Femasys announced its financial results for the third quarter ended September 30, 2024.
The company reported a significant increase in sales, primari...

$Femasys (FEMY.US)$ Reuters
1 min ago
Femasys Announces Issued U.S. Patent Covering Fembloc® Device for Female Permanent Birth Control

$Femasys (FEMY.US)$
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
Femasys Inc. (NASDAQ: FEMY) announces the issuance of U.S. Patent No. 12,12796 by the USPTO for its FemBloc® permanent birth control device. The patent, expiring no earlier than 2039, strengthens the company's intellectual property position for its leading therapeutic product candidate. This adds to Femasys' portfolio of over 180 patents globally, protecting their suite of prod...

$Femasys (FEMY.US)$ Reuters· 1 min ago
Femasys Announces Partnership With Boston IVF, Prominent Network of Fertility Centers, to Offer Femaseed

$Femasys (FEMY.US)$
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribut...

$Femasys (FEMY.US)$ Reuters
·3 mins ago
Femasys Secures Strategic Distribution Partnerships for Commercialization of Femaseed® for Over $1.3M in Spanish Market